Stocks Health care KROS

NASDAQ · Health care

Keros Therapeutics, Inc. (KROS)

Keros Therapeutics, Inc. brought in $15M of revenue over the twelve months to June 30, 2026, down 93.6% from a year earlier. It posted a net loss of $83.2M. Operating cash flow minus capital spending left $106M of free cash flow in fiscal 2025. At June 30, 2026 it held $257.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 3, 2026.

What Keros Therapeutics, Inc. does

Keros Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KROS.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Where KROS ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Keros Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 11, 2026
   Form DEL AM filing DEL AM
2. September 10, 2026
   Shelf registration to sell securities S-3
3. September 8, 2026
   Other event 8-K
4. August 3, 2026
   Investor disclosure 8-K
5. August 3, 2026
   Quarterly report 10-Q · period to June 30, 2026
6. August 3, 2026
   Quarterly results 8-K
7. July 30, 2026
   Investor disclosure 8-K
8. July 29, 2026
   Passive stake changed SCHEDULE 13G/A
9. July 22, 2026
   Executive or director change 8-K
10. July 17, 2026
    Passive stake (5% or more) SCHEDULE 13G

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 20, 2026. Insider transactions on SEC

What is KROS worth? A DCF from its reported cash flow

Insider trades

What the people running Keros Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about KROS

What does Keros Therapeutics, Inc. do?

Keros Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KROS.

Is Keros Therapeutics, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $83.2M on revenue of $15M.

How much revenue does Keros Therapeutics, Inc. make?

Over the twelve months to June 30, 2026 Keros Therapeutics, Inc. reported revenue of $15M. That is 93.6% less than a year earlier.

When did Keros Therapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 3, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the form DEL AM filing from September 11, 2026.

Similar companies

Compare KROS with

Compare KROS with any company

Follow KROS

Get an email when Keros Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow KROS: get an email when it files

Where the numbers come from

Financial figures are the values Keros Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.